Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TEAD3 | Q99594 | 2/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | UGCG | Q16739 | 2/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18936048 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHRTEAD3HRH4 | |
| SCHEMBL1469764 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHRTEAD3HRH4 | |
| SCHEMBL2246824 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHRTEAD3HRH4 | |
| SCHEMBL1164446 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHRTEAD3HRH4 | |
| SCHEMBL20231370 | 0.98 | TSHR (0.50) | L3MBTL1TDP1TSHRTEAD3HRH4 | |
| SCHEMBL3269931 | 0.93 | TSHR (0.52) | L3MBTL1TDP1TSHRTEAD3HRH4 | |
| SCHEMBL24675567 | 0.90 | L3MBTL1 (0.48) | L3MBTL1TDP1TSHRTEAD3HRH4 | |
| SCHEMBL29026158 | 0.86 | L3MBTL1 (0.40) | L3MBTL1TDP1TSHRTEAD3CA1 | |
| SCHEMBL101220 | 0.86 | L3MBTL1 (0.53) | L3MBTL1TDP1TSHRTEAD3HRH4 | |
| SCHEMBL20561263 | 0.85 | L3MBTL1 (0.53) | L3MBTL1TDP1TSHRTEAD3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4186888-B1 | COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12404232-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250228777-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2025-07-17 | — | — | US | disclosed |
| US-12324859-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-12263248-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12151995-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240124388-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-04-18 | — | — | US | disclosed |
| EP-4286012-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20090197201-A1 | FLUOROSURFACTANTS | MERCK PATENT GESELLSCHAFT (DE) | 2009-08-06 | — | — | US | disclosed |
| US-20090197201-A1 | FLUOROSURFACTANTS | MERCK PATENT GESELLSCHAFT (DE) | 2009-08-06 | — | — | US | disclosed |
| EP-2035129-A1 | FLUOROSURFACTANTS | Merck Patent GmbH (DE) | 2009-03-18 | — | — | EP | disclosed |
| EP-1465876-B1 | LONG CHAIN FATTY ALCOHOL SUBSTITUENTS IN ANTINEOPLASTIC AGENTS | PFAENDLER HANS RUDOLF (DE) | 2008-11-05 | — | — | EP | disclosed |
| EP-1465876-B1 | LONG CHAIN FATTY ALCOHOL SUBSTITUENTS IN ANTINEOPLASTIC AGENTS | PFAENDLER HANS RUDOLF (DE) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008003443-A1 | FLUOROSURFACTANTS | MERCK PATENT GMBH (DE) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008003443-A1 | FLUOROSURFACTANTS | MERCK PATENT GMBH (DE) | 2008-01-10 | — | — | WO | disclosed |
| US-20040266747-A1 | Long chain fatty alcohol substituents in antineoplastic agents | PFAENDLER HANS R (DE) | 2004-12-30 | — | — | US | disclosed |
| EP-1465876-A1 | LONG CHAIN FATTY ALCOHOL SUBSTITUENTS IN ANTINEOPLASTIC AGENTS | Pfaendler, Hans Rudolf (DE) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003055864-A1 | LONG CHAIN FATTY ALCOHOL SUBSTITUENTS IN ANTINEOPLASTIC AGENTS | PFAENDLER HANS RUDOLF (DE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324859-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | L3MBTL1 869/4885TDP1 3724/4885TSHR 3089/4885 |
| US-12151995-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | L3MBTL1 869/4885TDP1 3724/4885TSHR 3089/4885 |
| US-12263248-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | L3MBTL1 869/4885TDP1 3724/4885TSHR 3089/4885 |
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PHOSPHO1, LIPC, SDCBP | L3MBTL1 264/4885TDP1 2108/4885TSHR 4134/4885 |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | SIN3A, PLIN3, MSR1 | L3MBTL1 632/4885TDP1 4468/4885TSHR 540/4885 |
| US-20040266747-A1 | Long chain fatty alcohol substituents in antineoplastic agents | FASN, ELOVL3, ELOVL1 | L3MBTL1 1168/4885TDP1 1226/4885TSHR 2493/4885 |
| US-12404232-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | L3MBTL1 869/4885TDP1 3724/4885TSHR 3089/4885 |
| US-20240124388-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | L3MBTL1 869/4885TDP1 3724/4885TSHR 3089/4885 |
| US-20090197201-A1 | FLUOROSURFACTANTS | CBR3, SCO2, FPR3 | L3MBTL1 4159/4885TDP1 4231/4885TSHR 1047/4885 |
| US-20250228777-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | L3MBTL1 869/4885TDP1 3724/4885TSHR 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.